Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Prepaid Assets (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Prepaid Assets for 7 consecutive years, with $10.5 million as the latest value for Q4 2025.

  • Quarterly Prepaid Assets rose 4.22% to $10.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.5 million through Dec 2025, up 4.22% year-over-year, with the annual reading at $10.5 million for FY2025, 4.22% up from the prior year.
  • Prepaid Assets for Q4 2025 was $10.5 million at 4D Molecular Therapeutics, up from $7.3 million in the prior quarter.
  • The five-year high for Prepaid Assets was $11.1 million in Q1 2025, with the low at $3.3 million in Q3 2021.
  • Average Prepaid Assets over 5 years is $7.6 million, with a median of $7.9 million recorded in 2023.
  • The sharpest move saw Prepaid Assets surged 90.28% in 2021, then fell 17.73% in 2022.
  • Over 5 years, Prepaid Assets stood at $8.5 million in 2021, then fell by 17.73% to $7.0 million in 2022, then increased by 20.11% to $8.4 million in 2023, then rose by 20.33% to $10.1 million in 2024, then rose by 4.22% to $10.5 million in 2025.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $10.5 million, $7.3 million, and $10.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.